The Brazilian TP53 mutation (R337H) and sarcomas

7Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

Sarcomas represent less than 1% of all solid neoplasms in adults and over 20% in children. Their etiology is unclear, but genetic susceptibility plays an important role in this scenario. Sarcoma is central in Li-Fraumeni Syndrome (LFS), a familial predisposition cancer syndrome. In Brazil, the high prevalence of p.Arg337His mutations in the TP53 gene brings about a unique condition: a cluster of LFS. In the present work, we studied 502 sarcoma patients not selected by age or family history in an attempt to assess the impact of the socalled "Brazilian germline TP53 mutation" (p.Arg337His) on this tumor type. We found that 8% of patients are carriers, with leiomyosarcoma being the main histologic type of sarcoma, corresponding to 52.5% of the patients with the mutated TP53 gene. These findings emphasize the importance of genetic counseling and can better guide the management of sarcoma patients.

Cite

CITATION STYLE

APA

Volc, S. M., Ramos, C. R. N., Galvao, H. D. C. R., Felicio, P. S., Coelho, A. S., Berardineli, G. N., … Palmero, E. I. (2020). The Brazilian TP53 mutation (R337H) and sarcomas. PLoS ONE, 15(1). https://doi.org/10.1371/journal.pone.0227260

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free